Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases
Journal for ImmunoTherapy of Cancer2021Vol. 9(12), pp. e003730–e003730
Citations Over TimeTop 10% of 2021 papers
Giuseppe Minniti, Gaetano Lanzetta, Luca Capone, Martina Giraffa, Ivana Russo, Francesco Cicone, Alessandro Bozzao, Filippo Alongi, Luca Nicosia, G Fineschi, Luca Marchetti, Tommaso Tufo, Federico Bianciardi, Vincenzo Esposito, Piercarlo Gentile, Sergio Paolini
Abstract
Postoperative fSRS in combination with immunotherapy decreases the incidence of LMD and DBF in patients with resected BM from NSCLC and melanoma as compared with fSRS alone, reducing the rate of neurological death and prolonging survival.
Related Papers
- → A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes(2016)117 cited
- → Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases(2018)92 cited
- → Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment(2023)13 cited
- → Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(2023)7 cited
- → Porównanie pośrednie wyników leczenia chorych na zaawansowane/przerzutowe czerniaki za pomocą niwolumabu lub pembrolizumabu – analiza wieloośrodkowa(2020)1 cited